Mutation detail:
| Mutation site | E484K |
| Virus | SARS-CoV-2 |
Mutation level  |
Amino acid level |
| Gene/protein/region type | S |
| Gene ID | 43740568 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | - |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | NC_045512.2 |
| Drug/antibody/vaccine | mAb_D14-resistant,mAb_F05-resistant,mAb_F10-resistant,mAb_F20-resistant,mAb_G12-resistant,mAb_H20-resistant,mAb_I15-resistant,mAb_I21-resistant,mAb_J13-resistant,mAb_Patient Convalescent plasma-resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | Yes |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Spike glycoprotein |
| Uniprot protein ID | P0DTC2 |
| Protein length | 1273 amino acids |
| Protein description | Spike protein is one of the structural proteins of SARS-CoV-2. The monomeric protein consists of one large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail at C-terminus. It encompasses 22 glycosylation sites. S protein cleaves into two subunits namely S1 and S2 following receptor recognition. Receptor Binding Domain (RBD) in S1 subunit plays a major role in ACE2 receptor binding. |
Literature information:
| Pubmed ID | 33398278 |
| Clinical information | No |
| Disease | - |
| Published year | 2020 |
| Journal | bioRxiv |
| Title | SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma |
| Author | Emanuele Andreano, Giulia Piccini, Danilo Licastro, Lorenzo Casalino, Nicole V Johnson |
| Evidence | At day 73, an E484K substitution in the receptor-binding domain (RBD) occurred, followed at day 80 by an insertion in the NTD N5 loop containing a new glycan sequon, which generated a variant completely resistant to plasma neutralization. |